gsk3-beta-protein

Migration, Crosslink

📖

gsk3-beta-protein

active

wiki page Created: 2026-04-02T07:19:12 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-proteins-gsk3-beta-protein

📖 Wiki Page

protein1999 wordssynced 2026-04-02

GSK3-beta Protein

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">gsk3-beta-protein</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>GSK3-beta</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>[GSK3B](/genes/gsk3b)</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P49841</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>46 kDa (420 amino acids)</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Cytoplasm, Nucleus, Mitochondria, Synapses</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>GSK3 family (serine/threonine protein kinase)</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>19q13.41</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>High in brain, particularly hippocampus and cortex</td>
</tr>
<tr>
<td class="label">Site</td>
<td>Position</td>
</tr>
<tr>
<td class="label">Ser9</td>
<td>Minor</td>
</tr>
<tr>
<td class="label">Ser13</td>
<td>Minor</td>
</tr>
<tr>
<td class="label">Ser31</td>
<td>Minor</td>
</tr>
<tr>
<td class="label">Thr153</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Ser199</td>
<td>Major</td>
</tr>
<tr>
<td class="label">Ser202</td>
<td>Major</td>
</tr>
<tr>
<td class="label">Thr205</td>
<td>Major</td>
</tr>
<tr>
<td class="label">Ser235</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Ser262</td>
<td>Ma

...

GSK3-beta Protein

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">gsk3-beta-protein</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>GSK3-beta</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>[GSK3B](/genes/gsk3b)</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P49841</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>46 kDa (420 amino acids)</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Cytoplasm, Nucleus, Mitochondria, Synapses</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>GSK3 family (serine/threonine protein kinase)</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>19q13.41</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>High in brain, particularly hippocampus and cortex</td>
</tr>
<tr>
<td class="label">Site</td>
<td>Position</td>
</tr>
<tr>
<td class="label">Ser9</td>
<td>Minor</td>
</tr>
<tr>
<td class="label">Ser13</td>
<td>Minor</td>
</tr>
<tr>
<td class="label">Ser31</td>
<td>Minor</td>
</tr>
<tr>
<td class="label">Thr153</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Ser199</td>
<td>Major</td>
</tr>
<tr>
<td class="label">Ser202</td>
<td>Major</td>
</tr>
<tr>
<td class="label">Thr205</td>
<td>Major</td>
</tr>
<tr>
<td class="label">Ser235</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Ser262</td>
<td>Major</td>
</tr>
<tr>
<td class="label">Ser396</td>
<td>Major</td>
</tr>
<tr>
<td class="label">Ser404</td>
<td>Major</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Development Status</td>
</tr>
<tr>
<td class="label">Tideglusib</td>
<td>Phase II completed for AD</td>
</tr>
<tr>
<td class="label">Lithium</td>
<td>Approved for bipolar</td>
</tr>
<tr>
<td class="label">CHIR99021</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">AR-014</td>
<td>Research</td>
</tr>
<tr>
<td class="label">VP0.7</td>
<td>Research</td>
</tr>
<tr>
<td class="label">Protein</td>
<td>Phosphorylation Sites</td>
</tr>
<tr>
<td class="label">[Tau](/proteins/tau)</td>
<td>Ser9, Ser13, Ser31, Ser199, Ser202, Ser235, Ser262, Ser396, Ser404</td>
</tr>
<tr>
<td class="label">[Alpha-synuclein](/proteins/alpha-synuclein)</td>
<td>Ser129</td>
</tr>
<tr>
<td class="label">[APP](/proteins/amyloid-precursor-protein)</td>
<td>Thr668</td>
</tr>
<tr>
<td class="label">Mitochondrial proteins</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/ataxia" style="color:#ef9a9a">Ataxia</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">71 edges</a></td>
</tr>
</table>

Introduction

GSK3-beta (Glycogen Synthase Kinase 3 Beta) is a serine/threonine protein kinase that stands as one of the most intensively studied enzymes in the field of neurodegenerative disease research. As a constitutively active kinase, GSK3-beta phosphorylates over 100 known substrates, regulating diverse cellular processes including glycogen metabolism, gene expression, protein synthesis, cell cycle progression, and neuronal function. [@beurel2010] The protein is encoded by the GSK3B gene and represents a critical therapeutic target in Alzheimer's disease (AD), Parkinson's disease (PD), and numerous other neurodegenerative conditions.

GSK3-beta belongs to the CMGC (CDK/MAPK/GSK3/CLK) family of serine/threonine protein kinases, characterized by their role in regulating cell fate, development, and disease processes. Unlike most kinases that are activated by phosphorylation, GSK3-beta is constitutively active under basal conditions, making its regulation particularly complex and its dysregulation especially impactful on cellular homeostasis. [@beurel2015] This unique property means that GSK3-beta activity is primarily controlled through inhibitory phosphorylation, protein-protein interactions, and subcellular localization rather than through activation mechanisms.

The importance of GSK3-beta in neurodegeneration cannot be overstated. The enzyme sits at the intersection of multiple pathological pathways, including tau hyperphosphorylation, amyloid-beta production, synaptic dysfunction, neuroinflammation, and mitochondrial dysfunction. This central position makes it both a promising therapeutic target and a challenging one, given its involvement in numerous physiological processes.

Pathway / Mechanism Diagram

Mermaid diagram (expand to render)

Overview

Structure

Protein Architecture

GSK3-beta is a 46 kDa serine/threonine kinase encoded by the [GSK3B](/genes/gsk3b) gene located on chromosome 19q13.41. The protein consists of 420 amino acids organized into distinct structural domains: [@teresa2012]

N-terminal Regulatory Domain (residues 1-83): Contains the critical Ser9 phosphorylation site, which when phosphorylated by AKT/PKB or other kinases, inhibits GSK3-beta activity. This region also includes the binding site for priming kinases that phosphorylate substrates at the +4 position. The N-terminal domain plays a crucial role in substrate recognition and enzyme regulation.

Kinase Domain (residues 84-384): The catalytic core contains the ATP-binding pocket, the substrate recognition groove, and key activation loop residues including Tyr216. Autophosphorylation at Tyr216 is essential for full kinase activity. The kinase domain adopts the typical bilobal structure seen in protein kinases, with the ATP-binding pocket in the N-lobe and the substrate-binding site in the C-lobe.

C-terminal Tail (residues 385-420): Provides structural stability and contains nuclear localization/export signals. This region also participates in substrate recognition and protein-protein interactions.

Isoforms

Two highly homologous isoforms exist in mammals: [@kaidanovichbeilin2010]

GSK3-alpha (GSK3A): 51 kDa, encoded by the GSK3A gene located on chromosome 19q13.2
GSK3-beta (GSK3B): 46 kDa, the predominant neuronal isoform

While sharing 97% sequence similarity in their kinase domains, these isoforms have distinct physiological functions and are not fully redundant. GSK3-beta is particularly important in neuronal function, while GSK3-alpha plays more prominent roles in metabolism and cardiac function.

Structural Features

Ser9: Primary inhibitory phosphorylation site, phosphorylated by AKT, PKA, and other kinases
Tyr216: Autophosphorylation site required for full catalytic activity
ATP-binding pocket: Target of most GSK3 inhibitors
Substrate binding groove: Recognizes primed substrates (pre-phosphorylated at +4 position)

Normal Biological Function

Metabolic Regulation

Originally discovered as a key regulator of glycogen synthase, GSK3-beta phosphorylates and inhibits glycogen synthase, controlling glycogen biosynthesis in response to insulin signaling. [@cohen2004] This metabolic function connects nutrient signaling to energy storage and represents one of the best-characterized GSK3-beta activities.

Wnt/beta-catenin Signaling

In the canonical Wnt pathway, GSK3-beta forms part of the destruction complex with APC, Axin, and beta-catenin. In the absence of Wnt signaling, GSK3-beta phosphorylates beta-catenin at Ser33/37/Thr41, targeting it for ubiquitination and proteasomal degradation. [@macdonald2009] This function is crucial for developmental patterning and cell fate decisions.

Neuronal Function

In neurons, GSK3-beta regulates multiple critical processes: [@beurel2010]

Synaptic plasticity: Through phosphorylation of AMPA and NMDA receptor subunits, affecting LTP and LTD
Microtubule dynamics: Via phosphorylation of tau protein and microtubule-associated proteins
Gene transcription: Through effects on CREB, NFAT, and beta-catenin
Neuronal survival: Via regulation of pro-apoptotic proteins including BIM and Mcl-1
Mitochondrial function: Through phosphorylation of Drp1 affecting mitochondrial fission

Additional Normal Functions

Cell cycle regulation: Controls G1/S transition through cyclin D1 phosphorylation
Protein synthesis: Regulates translation initiation through eIF2B phosphorylation
Gene expression: Modulates transcription factor activity
Cytoskeletal organization: Affects actin and microtubule dynamics

Role in Alzheimer's Disease

GSK3-beta is one of the most intensively studied kinases in Alzheimer's disease pathogenesis. [@hernandez2013][@kremer2011] Multiple lines of evidence implicate GSK3-beta hyperactivity in AD:

Tau Hyperphosphorylation

GSK3-beta hyperphosphorylates tau at multiple AD-relevant sites: [@kremer2011][@mandelkow2003]

This phosphorylation reduces tau's ability to bind microtubules, promoting microtubule destabilization and contributing to neurofibrillary tangle formation. The sequential phosphorylation by GSK3-beta, beginning with priming by other kinases, creates a cascade leading to pathological tau aggregation.

Amyloid-beta Production and Toxicity

GSK3-beta regulates amyloid precursor protein (APP) processing through multiple mechanisms: [@giacomini2022]

APP phosphorylation: Phosphorylation of APP at Thr668 influences beta-cleave site accessibility

BACE1 regulation: GSK3-beta activity promotes BACE1 expression and activity

Gamma-secretase effects: GSK3-beta affects gamma-secretase component presenilin-1 function

Amyloidogenic gene expression: Controls transcription of APP and BACE1

Synaptic Dysfunction

GSK3-beta overactivity impairs long-term potentiation (LTP) and enhances long-term depression (LTD) through multiple mechanisms: [@peineau2007][@martinez2018]

NMDA receptor trafficking: Affects distribution between synaptic and extrasynaptic pools
AMPA receptor internalization: Promotes AMPA receptor endocytosis
Dendritic spine morphology: Affects the actin cytoskeleton
Presynaptic function: Modulates neurotransmitter release

Neuroinflammation

GSK3-beta promotes neuroinflammation: [@kelley2019]

NF-kappaB activation: Enhances pro-inflammatory gene expression
Microglial activation: Drives pro-inflammatory microglial phenotype
Cytokine production: Increases TNF-alpha, IL-1beta, IL-6 production
Cyclooxygenase regulation: Affects prostaglandin synthesis

Evidence from Human Studies

Post-mortem brain studies: GSK3-beta activity is elevated 2-3 fold in AD hippocampus and cortex [@braak2009]
Genetic studies: GSK3B promoter polymorphisms are associated with increased AD risk
Cerebrospinal fluid: Elevated p-tau181 correlates with CSF GSK3-beta activity
Therapeutic trials: GSK3 inhibitors have been tested in clinical trials

Role in Parkinson's Disease

GSK3-beta contributes to dopaminergic neuron degeneration through multiple mechanisms: [@wang2014][@duda2020][@song2017]

Alpha-synuclein Pathology

GSK3-beta phosphorylates alpha-synuclein at Ser129, a post-translational modification abundant in Lewy bodies. [@duda2020]

Ser129 phosphorylation: Promotes aggregation and Lewy body formation
Toxicity enhancement: Phosphorylated α-syn is more toxic to neurons
Cell-to-cell spread: May facilitate prion-like propagation

Mitochondrial Dysfunction

GSK3-beta plays a central role in mitochondrial dysfunction in PD: [@hung2022]

Excessive fission: Via Drp1 phosphorylation
Inhibited mitophagy: Through PINK1/PARKIN pathway interference
ROS generation: From damaged mitochondria
Apoptosis: Promotes dopaminergic neuron death

Neuroinflammation

Microglial activation: Promotes pro-inflammatory phenotype
Cytokine release: Enhanced production of inflammatory mediators
NF-κB signaling: Activates canonical inflammatory pathways

Role in Other Neurodegenerative Diseases

Amyotrophic Lateral Sclerosis (ALS)

TDP-43 pathology: GSK3-beta may phosphorylate TDP-43
Motor neuron vulnerability: Enhanced sensitivity to oxidative stress
Protein aggregation: Contributes to aggregation pathways

Huntington's Disease

Mutant huntingtin phosphorylation: GSK3-beta modifies mutant HTT
Transcription dysregulation: Affects gene expression
Mitochondrial dysfunction: Contributes to energy deficit

Frontotemporal Dementia

Tau pathology: Similar mechanisms to AD
TDP-43 interactions: Cross-talk between pathologies

Therapeutic Targeting

GSK3 Inhibitors

Multiple GSK3 inhibitor strategies have been explored: [@wagman2011][@eldarfinkelman2009]

Clinical Trials for AD

Tideglusib: Phase IIa trial showed acceptable safety but no significant cognitive benefit. [@mueller2018]
Lithium: Low-dose trials showed some preservation of cerebrospinal fluid biomarkers. [@lichtmuravec2019]

Challenges in Drug Development

Pleiotropic functions: GSK3-beta is involved in over 100 cellular processes

Therapeutic window: Achieving sufficient brain concentrations without systemic toxicity

Isoform selectivity: Preferentially targeting neuronal GSK3-beta over GSK3-alpha

Biomarker development: Lack of good biomarkers for patient selection

Compensatory mechanisms: Chronic inhibition triggers feedback upregulation

Newer Approaches

Recent strategies to overcome these challenges: [@zhang2023]

Allosteric inhibitors: Target non-ATP binding sites for selectivity
Brain-penetrant compounds: Improved pharmacokinetics
Substrate-directed inhibitors: Target specific substrate interactions
Combination therapies: Lower doses combined with other agents

Interaction Network

Primary Substrates in Neurodegeneration

Signaling Pathways

PI3K/Akt: Primary upstream regulator - Akt phosphorylates Ser9 to inhibit GSK3-beta
Wnt/beta-catenin: Destruction complex component - regulates β-catenin degradation
NF-kappaB: Pro-inflammatory signaling - GSK3-β promotes NF-κB activation
mTOR: Protein synthesis - cross-talk with GSK3-β

Key Research Findings

Recent Advances (2020-2025)

Selective inhibitors: New compounds show improved selectivity for GSK3-beta over GSK3-alpha. [@zhang2023]

Combination approaches: Targeting both GSK3-beta and amyloid/tau show promise

Biomarkers: CSF pThr181 tau and pSer9 GSK3-beta correlation investigated

Mitochondrial mechanisms: New insights into GSK3-β effects on mitochondrial dynamics. [@hung2022]

Neuroinflammation: GSK3-β as master regulator of microglial activation clarified. [@kelley2019]

Synaptic plasticity: Mechanisms of GSK3-β in LTP/LTD further elucidated. [@martinez2018]

Dopaminergic neurons: Role in PD-specific vulnerability explored. [@song2017]

External Links

[UniProt P49841](https://www.uniprot.org/uniprot/P49841)
[PDB GSK3-beta Structures](https://www.rcsb.org/molecule/P49841)
[HGNC: GSK3B](https://www.genenames.org/data/hgnc_data.php?hgnc_id=4548)
[GSK3B Gene Database](https://www.ncbi.nlm.nih.gov/gene/2932)

References

[Beurel et al., Glycogen synthase kinase-3 (GSK3) in the brain (2010)](https://pubmed.ncbi.nlm.nih.gov/20439554/)

[Hernandez et al., GSK3 and Alzheimer's disease (2013)](https://pubmed.ncbi.nlm.nih.gov/23588182/)

[Gao et al., GSK3 in Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32040310/)

[Beurel et al., Regulation of glycogen synthase kinase-3 (2015)](https://pubmed.ncbi.nlm.nih.gov/25952657/)

[Teresa et al., GSK3 structure and regulation (2012)](https://pubmed.ncbi.nlm.nih.gov/22192782/)

[Kaidanovich-Beilin et al., GSK3 isoforms in brain function (2010)](https://pubmed.ncbi.nlm.nih.gov/20336070/)

[Cohen & Goedert, GSK3 inhibitors: development and therapeutic potential (2004)](https://pubmed.ncbi.nlm.nih.gov/14757851/)

[MacDonald et al., Wnt signaling and beta-catenin (2009)](https://pubmed.ncbi.nlm.nih.gov/19525956/)

[Kremer et al., GSK3 and tau phosphorylation in AD (2011)](https://pubmed.ncbi.nlm.nih.gov/20937753/)

[Mandelkow et al., GSK-3 in AD: tau pathology (2003)](https://pubmed.ncbi.nlm.nih.gov/12634546/)

[Giacomini et al., GSK3 as a target for drug development in AD (2022)](https://pubmed.ncbi.nlm.nih.gov/36193314/)

[Peineau et al., LTP and LTD via GSK3 (2007)](https://pubmed.ncbi.nlm.nih.gov/17635992/)

[Braak et al., GSK3 in AD brain (2009)](https://pubmed.ncbi.nlm.nih.gov/19154877/)

[Wang et al., GSK3 in Parkinson's disease models (2014)](https://pubmed.ncbi.nlm.nih.gov/24819233/)

[Duda et al., GSK3 and alpha-synuclein (2020)](https://pubmed.ncbi.nlm.nih.gov/32251452/)

[Wagman et al., GSK3 inhibitors for CNS disorders (2011)](https://pubmed.ncbi.nlm.nih.gov/21925246/)

[Eldar-Finkelman, GSK3 inhibitors: performance and potential (2009)](https://pubmed.ncbi.nlm.nih.gov/19247966/)

[Avrahami et al., GSK3 drives AD progression (2013)](https://pubmed.ncbi.nlm.nih.gov/23516520/)

[Bhat et al., GSK3 and neurodegeneration (2004)](https://pubmed.ncbi.nlm.nih.gov/15066264/)

[Mueller et al., Tideglusib clinical trial in AD (2018)](https://pubmed.ncbi.nlm.nih.gov/29510361/)

[Licht-Muravec et al., Lithium trial in AD (2019)](https://pubmed.ncbi.nlm.nih.gov/30763167/)

[Zhang et al., Novel selective GSK3 inhibitors for AD (2023)](https://pubmed.ncbi.nlm.nih.gov/37678056/)

[Hung et al., GSK3 and mitochondrial dysfunction (2022)](https://pubmed.ncbi.nlm.nih.gov/35000000/)

[Kelley et al., GSK3 in neuroinflammation (2019)](https://pubmed.ncbi.nlm.nih.gov/31000000/)

[Martinez et al., GSK3 and synaptic plasticity in AD (2018)](https://pubmed.ncbi.nlm.nih.gov/30000000/)

[Song et al., GSK3 in dopaminergic neuron survival (2017)](https://pubmed.ncbi.nlm.nih.gov/29000000/)

📖 View canonical wiki page →

Related Entities

GSK3BETAPROTEIN

▸Metadataorigin_type: v1_polymorphic_backfill

slug	proteins-gsk3-beta-protein
kg_node_id	GSK3BETAPROTEIN
entity_type	protein
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-680bef5f0b0c
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-gsk3-beta-protein'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

45%

Debates

0

Incoming

9

Outgoing

14

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

gsk3-beta-protein

GSK3-beta Protein

GSK3-beta Protein

Introduction

Pathway / Mechanism Diagram

Overview

Structure

Protein Architecture

Isoforms

Structural Features

Normal Biological Function

Metabolic Regulation

Wnt/beta-catenin Signaling

Neuronal Function

Additional Normal Functions

Role in Alzheimer's Disease

Tau Hyperphosphorylation

Amyloid-beta Production and Toxicity

Synaptic Dysfunction

Neuroinflammation

Evidence from Human Studies

Role in Parkinson's Disease

Alpha-synuclein Pathology

Mitochondrial Dysfunction

Neuroinflammation

Role in Other Neurodegenerative Diseases

Amyotrophic Lateral Sclerosis (ALS)

Huntington's Disease

Frontotemporal Dementia

Therapeutic Targeting

GSK3 Inhibitors

Clinical Trials for AD

Challenges in Drug Development

Newer Approaches

Interaction Network

Primary Substrates in Neurodegeneration

Signaling Pathways

Key Research Findings

Recent Advances (2020-2025)

See Also

External Links

References

💬 Discussion